Literature DB >> 16310250

Complement in BuB/BnJ mice revisited: serum C3 levels and complement opsonic activity are not elevated.

Inga Osmers1, Alexander J Szalai, Andrea J Tenner, Scott R Barnum.   

Abstract

With the exception of a few strains such as BuB/BnJ, complement activity in most inbred strains of mice is remarkably similar. The BuB/BnJ strain reportedly has high levels of complement activity and elevated serum levels of C3 and other complement proteins. However, we observed that BuB/BnJ mice have serum C3 levels comparable to those seen in C57BL/6, Balb/c and several other strains of inbred mice. More importantly, using bacteria as a substrate for activation and deposition of complement as a direct biological assay to assess serum complement opsonic activity, we found that BuB/BnJ mice do not have elevated complement activity compared to other inbred mouse strains. In contrast hemolytic assays indicate BuB/BnJ sera to be most active. These results indicate that accepted views regarding mouse serum complement activity need to be re-examined.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16310250     DOI: 10.1016/j.molimm.2005.10.004

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  10 in total

1.  A targeted complement-dependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancer.

Authors:  Michelle Elvington; Yuxiang Huang; B Paul Morgan; Fei Qiao; Nico van Rooijen; Carl Atkinson; Stephen Tomlinson
Journal:  Blood       Date:  2012-03-22       Impact factor: 22.113

2.  Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4.

Authors:  Daniela Bumbaca; Anne Wong; Elizabeth Drake; Arthur E Reyes; Benjamin C Lin; Jean-Philippe Stephan; Luc Desnoyers; Ben-Quan Shen; Mark S Dennis
Journal:  MAbs       Date:  2011-07-01       Impact factor: 5.857

3.  Comparison of immunopathology and locomotor recovery in C57BL/6, BUB/BnJ, and NOD-SCID mice after contusion spinal cord injury.

Authors:  Sabina Luchetti; Kevin D Beck; Manuel D Galvan; Richard Silva; Brian J Cummings; Aileen J Anderson
Journal:  J Neurotrauma       Date:  2010-02       Impact factor: 5.269

Review 4.  The complement cascade: Yin-Yang in neuroinflammation--neuro-protection and -degeneration.

Authors:  Jessy John Alexander; Aileen Judith Anderson; Scott Robert Barnum; Beth Stevens; Andrea Joan Tenner
Journal:  J Neurochem       Date:  2008-10-24       Impact factor: 5.372

5.  Deficiency in complement C1q improves histological and functional locomotor outcome after spinal cord injury.

Authors:  Manuel D Galvan; Sabina Luchetti; Adrian M Burgos; Hal X Nguyen; Mitra J Hooshmand; Frank P T Hamers; Aileen J Anderson
Journal:  J Neurosci       Date:  2008-12-17       Impact factor: 6.167

6.  Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV.

Authors:  Veronique Minard-Colin; Yan Xiu; Jonathan C Poe; Mayuka Horikawa; Cynthia M Magro; Yasuhito Hamaguchi; Karen M Haas; Thomas F Tedder
Journal:  Blood       Date:  2008-05-21       Impact factor: 22.113

7.  N-Formyl-Perosamine Surface Homopolysaccharides Hinder the Recognition of Brucella abortus by Mouse Neutrophils.

Authors:  Ricardo Mora-Cartín; Carlos Chacón-Díaz; Cristina Gutiérrez-Jiménez; Stephany Gurdián-Murillo; Bruno Lomonte; Esteban Chaves-Olarte; Elías Barquero-Calvo; Edgardo Moreno
Journal:  Infect Immun       Date:  2016-05-24       Impact factor: 3.441

8.  Complement component 5 contributes to poor disease outcome in humans and mice with pneumococcal meningitis.

Authors:  Bianca Woehrl; Matthijs C Brouwer; Carmen Murr; Sebastiaan G B Heckenberg; Frank Baas; Hans W Pfister; Aeilko H Zwinderman; B Paul Morgan; Scott R Barnum; Arie van der Ende; Uwe Koedel; Diederik van de Beek
Journal:  J Clin Invest       Date:  2011-09-19       Impact factor: 14.808

9.  Contribution of complement activation pathways to neuropathology differs among mouse models of Alzheimer's disease.

Authors:  Maria I Fonseca; Shu-Hui Chu; Alisia M Berci; Marie E Benoit; Douglas G Peters; Yuko Kimura; Andrea J Tenner
Journal:  J Neuroinflammation       Date:  2011-01-15       Impact factor: 8.322

10.  Expression of complement system components during aging and amyloid deposition in APP transgenic mice.

Authors:  Julia Reichwald; Simone Danner; Karl-Heinz Wiederhold; Matthias Staufenbiel
Journal:  J Neuroinflammation       Date:  2009-11-17       Impact factor: 8.322

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.